Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 8, 2009, Pages 1271-1276

  Radovits, B J ^a   Popa Diaconu, D A ^a   Popa, C ^a   Eijsbouts, A ^b   Laan, R F J M ^a   Van Riel, P L C M ^a   Fransen, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ELECTROCARDIOGRAM; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; CHOLESTEROL; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SEX FACTORS;

EID: 67651212165     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.089862     Document Type: Article

References (37)

1. del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-23.
2. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004;63:952-5.
3. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
4. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2006;32:435-42.
5. Crowson CS, Nicola PJ, Kremers HM, O'Fallon WM, Therneau TM, Jacobsen SJ, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005;52:3039-44.
6. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
7. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005;17:234-41.
8. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18:289-97.
9. Popa C, Netea MG, van Riel PL. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-62.
10. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
11. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A(2) to this atherogenic profile. Arthritis Rheum 2001;44:2761-7.
12. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J 2006;119:U2125.
13. Boers M, Nurmohamed MT, Doelman CJA, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
14. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 2007;3:845-52.
15. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
16. Popa C, Netea MG, Radstake T, van der Meer JWM, Stalenhoef AFH, van Riel PL, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
17. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1489-97.
18. Wallberg-Jonsson S, Ohman ML, Rantapaa-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004;33:373-9.
19. Welsing PMJ, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol 2004;31:14-21.
20. Rothman KJ, Greenland S. Case-control studies. In: Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia, Lippincott-Raven, 1998:97-8.
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease-activity scores that include 28-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid-arthritis. Arthritis Rheum 1995;38:44-8.
22. Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem 2004;37:785-90.
23. Donders ART, van der Heijden GJMG, Stijnen T, Moons KGM. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-91.
24. Folsom A, Aleksic N, Cattellier D. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002;144:233-8.
25. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
26. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-32.
27. Banerjee S, Compton AP, Hooker RS, Cypher DJ, Reimold A, Brilakis ES, et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 2008;101:1201-5.
28. Bartoloni Bocci E, Marchesi S, Delle Monache F, Vaudo G, Giordano A, Ragni Alunni F, et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Reumatismo 2005;57:16-21.
29. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31-5.
30. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002;22:1637-41.
31. Hansel S, Lassig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003;170:177-80.
32. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
33. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
34. Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 2007;26:1228-33.
35. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006;55:531- 6.
36. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
37. Davis JM, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005;32:1856-62.